| Literature DB >> 28054019 |
Ceyda Acilan1, Buse Cevatemre2, Zelal Adiguzel1, Didem Karakas2, Engin Ulukaya3, Nádia Ribeiro4, Isabel Correia4, João Costa Pessoa4.
Abstract
Three copper(II) complexes, Cu(Sal-Gly)(phen), Cu(Sal-Gly)pheamine, Cu(Sal-Gly)phepoxy were synthesized and characterized for their anticancer properties and mechanism of action (Acilan et al., in press) [1]. Here, we provide supporting data on colon cancer cell lines complementing our previous findings in cervix cells. This paper also contains a data table for the fold changes and p-values of all genes analyzed in this study via a custom RT-qPCR array. All compounds induced DNA damage (based on 8-oxo-guanidine, ɣH2AX staining in cells) and apoptosis (based on elevated DNA condensation/fragmentation, Annexin V staining, caspase 3/7 activity and mitochondrial membrane depolarization) in HCT-116 colon cancer cells. The increase in oxidative stress was also further confirmed in these cells. Further interpretation of the data presented here can be found in the article entitled "Synthesis, biological characterization and evaluation of molecular mechanisms of novel copper complexes as anticancer agents" (Acilan et al., in press) [1].Entities:
Year: 2016 PMID: 28054019 PMCID: PMC5194229 DOI: 10.1016/j.dib.2016.11.063
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Scheme 1Formulation of the complexes.
List of genes studied in the RT-qPCR array. Three housekeeping genes were used in each experiment and each gene was normalized to the average of housekeeping genes. Fold change was calculated as the fold increase compared to untreated controls. An average of two independent experiments (each done in duplicate) is shown on the Table. Standard (Std) errors represent deviations from the mean, and the p-values were calculated using paired samples t-test using SPSS 17.0 software. Only one gene, Harakiri, was found to be statistically significant above the cut-off value of 1.5 fold.
| Akt1 | 0.782 | 0.080 | 0.160 |
| Akt2 | 1.033 | 0.142 | 0.797 |
| APAF1 | 0.766 | 0.195 | 0.339 |
| ATG7 | 1.029 | 0.036 | 0.465 |
| ATM | 0.841 | 0.103 | 0.274 |
| ATR | 0.968 | 0.199 | 0.858 |
| AURKA | 1.173 | 0.312 | 0.577 |
| BAG1 | 1.048 | 0.028 | 0.243 |
| BAG3 | 1.060 | 0.158 | 0.688 |
| BAG4 | 1.163 | 0.386 | 0.657 |
| Bak1 | 0.874 | 0.313 | 0.670 |
| Bax | 1.076 | 0.511 | 0.867 |
| Bcl2 | 1.326 | 0.381 | 0.439 |
| BCL2A1 | ND | ND | ND |
| BCL10 | 0.778 | 0.315 | 0.501 |
| BCL2L2 | 1.221 | 0.158 | 0.299 |
| BCL2L10 | 1.309 | 0.841 | 0.695 |
| BCLAF1 | 0.720 | 0.234 | 0.340 |
| Bcl-xL | 1.148 | 0.306 | 0.619 |
| BECN1 | 1.312 | 0.322 | 0.402 |
| BFAR | 0.954 | 0.070 | 0.527 |
| BIRC2 | 0.760 | 0.202 | 0.342 |
| BIRC3 | 0.927 | 0.197 | 0.692 |
| BIRC4 | 1.000 | 0.145 | 1.000 |
| BIRC6 | 0.965 | 0.022 | 0.262 |
| BIRC8 | ND | ND | ND |
| Bid | 1.091 | 0.323 | 0.758 |
| Bik | 0.926 | 0.451 | 0.856 |
| Bim | 1.203 | 0.332 | 0.546 |
| BMI1 | 0.799 | 0.083 | 0.181 |
| BNIP1 | 1.188 | 0.316 | 0.556 |
| BNIP2 | 1.236 | 0.774 | 0.740 |
| BNIP3 | 0.713 | 0.273 | 0.376 |
| BNIP3L | 0.745 | 0.261 | 0.398 |
| CASP2 | 0.912 | 0.316 | 0.761 |
| CASP3 | 0.695 | 0.199 | 0.274 |
| CASP4 | 0.923 | 0.105 | 0.492 |
| CASP5 | 1.903 | 2.615 | 0.711 |
| CASP6 | 0.995 | 0.088 | 0.949 |
| CASP7 | 0.763 | 0.062 | 0.117 |
| CASP8 | 0.575 | 0.219 | 0.223 |
| CASP9 | 0.757 | 0.576 | 0.657 |
| CASP10 | 1.113 | 0.028 | 0.112 |
| CASP14 | 2.676 | 2.644 | 0.535 |
| CAT | 1.082 | 0.178 | 0.633 |
| CDC2 | 1.144 | 0.142 | 0.386 |
| CDC25A | 0.852 | 0.233 | 0.535 |
| CDK2 | 0.817 | 0.109 | 0.251 |
| CDK4 | 1.052 | 0.212 | 0.788 |
| DCR | 17.927 | 16.253 | 0.380 |
| DR4 | 0.867 | 0.041 | 0.134 |
| DR5 | 0.953 | 0.068 | 0.507 |
| ERCC1 | 0.682 | 0.802 | 0.675 |
| ERCC3 | 0.893 | 0.114 | 0.413 |
| FADD | 0.930 | 0.036 | 0.221 |
| Fas(TNFRSF6) | 0.837 | 0.065 | 0.175 |
| GPX1 | 1.160 | 0.466 | 0.713 |
| GRB2 | 0.897 | 0.060 | 0.250 |
| GSTP1 | 1.121 | 0.333 | 0.697 |
| HRK | 1.731 | 0.327 | 0.000 |
| LIG4 | 0.794 | 0.112 | 0.233 |
| MCL1 | 0.709 | 0.334 | 0.434 |
| MDM2 | 0.702 | 0.396 | 0.480 |
| MUTYH | 1.241 | 0.202 | 0.341 |
| NFKB1/p50 | 0.793 | 0.050 | 0.107 |
| Noxa | 1.150 | 0.269 | 0.576 |
| Nox1 | 2.129 | 0.989 | 0.353 |
| Nox4 | 3.428 | 3.769 | 0.530 |
| OGG1 | 1.121 | 0.104 | 0.349 |
| PRDX1 | 0.964 | 0.155 | 0.800 |
| Puma(BBC3) | 1.348 | 0.517 | 0.516 |
| P53 | 1.450 | 0.195 | 0.189 |
| RAD51 | 0.895 | 0.151 | 0.503 |
| RAD52 | 1.042 | 0.009 | 0.090 |
| RIPK2 | 1.050 | 0.109 | 0.633 |
| SIRT2 | 0.886 | 0.946 | 0.893 |
| SOD1 | 0.942 | 0.185 | 0.732 |
| TNFRSF11B(OPG) | 2.180 | 1.581 | 0.483 |
| XPA | 1.116 | 0.079 | 0.286 |
| XRCC5 | 0.862 | 0.005 | 0.016 |
Fig. 1UV–vis absorption spectra measured with increasing time (time interval between spectra=5 min) for solutions of the Cu-complexes in PBS. (A) Cu(Sal-Gly)(phen) 20 μM (0.6% DMSO) total time=55 min; (B) [Cu(Sal-Gly)(pheamine) 20 μM (0.6% DMSO) total time=55 min and (C) [Cu(Sal-Gly)(phepoxy) 60 μM (1% DMSO) total time=100 min. Arrows indicate changes with time.
Fig. 2First derivative X-band EPR spectra measured for frozen solutions (77 K) of the complexes with time. (A) Cu(Sal-Gly)(phen) 4.0 mM in MeOH, and Cu(Sal-Gly)(pheamino) (B) and Cu(Sal-Gly)(phepoxy) 1.0 mM in DMSO.
Fig. 3Circular dichroism spectra (1 cm optical path) of CT-DNA (60 μM) in the absence and presence of different % (v/v) of DMSO.
Fig. 4UV–vis absorption data: (A) Relative absorption values measured with time for solutions containing Cu(Sal-Gly)(phen) (20 μM) with and without CT-DNA (1 mol equivalent); (B) UV–vis absorption spectra measured for a solution of Cu(Sal-Gly)(pheamine) (40 μM) and increasing amounts of CT-DNA (from 0 to 180 μM); inset – changes observed in the ε values (M−1cm−1) at 256 and 278 nm. (C) UV–vis absorption spectra measured for a solution of Cu(Sal-Gly)(phepoxy) (27 μM) and increasing amounts of CT-DNA (from 0 to 28 μM). The arrow indicates increasing DNA concentration.
Fig. 5Cytotoxicity of the Cu compounds as determined by SRB analysis. Cytotoxicity in response to three different Cu-complexes was reevaluated using a different viability assay (SRB technique) upon increasing doses (0–12.5 µM) at different time points (24 h, 72 h) in a subset of cancer cells (A-549, HCT-116, HeLa). x-axis: concentration in µM, y-axis: cell viability normalized to untreated controls.
Fig. 6Changes in nuclear morphology in response to Cu complexes. HCT-116 cells displayed typical features of apoptosis such as fragmentation and condensation. HCT-116 cells treated with 12.5 μM of Cu complexes are shown in the figure. Insets indicate enlarged views of selected cells exhibiting these features.
Fig. 7Annexin V/PI staining supports apoptotic form of cell death in response to Cu compounds. HCT-116 cells were treated with the Cu complexes and were stained with Annexin V/dead cell marker and counted with a flow cytometer as described in materials and methods. (A) Representative plots for HCT-116 cells following 24 h drug exposure are shown in the figure. (B) The graphs represent averages from 2 independent experiments from 24 h of exposure (left graph) and 48 h of exposure (right graph), where 10.000 cells were scored. x-axis: % cells, y-axis: name of the drug, NC: negative control, mock treated cells.
Fig. 8Analysis of caspase 3/7 activity using a flow cytometric assay. HCT-116 cells were treated with the Cu-complexes and were stained using Caspase 3/7 kit and counted with a flow cytometer as described in materials and methods. (A) Representative plots for HCT-116 cells following 48 h drug exposure are shown in the figure. (B) The graphs represent averages from 2 independent experiments from 24 h of exposure (left graph) and 48 h of exposure (right graph), where 10.000 cells were scored. x-axis: % cells, y-axis: name of the drug, NC: negative control, mock treated cells.
Fig. 9Induction of MMP in response to Cu complexes. HCT-116 cells were treated with the Cu complexes and were stained using MitoPotential kit and counted with a flow cytometer as described in materials and methods. (A) Representative plots for HCT-116 cells following 48 h drug exposure are shown in the figure. (B) The graphs represent averages from 2 independent experiments from 24 h of exposure (left graph) and 48 h of exposure (right graph), where 10.000 cells were scored. x-axis: % cells, y-axis: name of the drug, NC: negative control, mock treated cells.
Fig. 10Increase in ROS in response to Cu-complexes. (A) Cells were pretreated with DCFDA with the indicated doses of Cu-complexes for 6–72 h and ROS were measured as described in materials and methods. Averages from three replicates from HCT-116 cells are shown in the graphs. y-axis: fold increase in DCFDA staining of cells relative to untreated controls, x-axis: concentration of Cu-complexes (µM). Asterisks indicate significance compared to untreated controls (paired samples t-test, p<0.05). (⁎:Cu(Sal-Gly)(pheamine), ⁎⁎: Cu(Sal-Gly)(phepoxy), ⁎⁎⁎: Cu(Sal-Gly)(phen)). (B) HCT-116 cells were treated with 12.5 µM of the Cu-complexes and lysed 24 h post incubation. The cellular GSSG/GSH (oxidized/reduced forms of glutathione) levels were measured, and an increase in oxidation was observed with all three Cu-complexes. Significance is indicated by asterisks (paired samples t-test, p<0.05).
Fig. 11Oxidative DNA damage induced by the Cu-complexes. HCT-116 cells were treated with the 12.5 μM of Cu complexes for 24 h and were stained for DNA (blue) and 8-oxo-guanine (red), the most common lesion in response to oxidative stress. 8-oxo-G staining was increased upon treatment with all Cu complexes.
Fig. 12Induction DNA double strand breaks as a result of treatment with the Cu-complexes. (A) HCT-116 cells were treated with IC90 values of the Cu complexes for 12 h, and were stained with both anti-phospho-Histone H2AX (Ser139) and anti-Histone H2AX antibodies, and quantified using a flow cytometer. Non-expressing quadrant indicates cells that do not express H2AX antigen, inactivated quadrant indicates the cells expressing H2AX without phosphorylation and activated quadrant indicates the ɣH2AX phosphorylated cells. The quantification of results is shown in the graphs. (B) In order to visually determine ɣH2AX positivity, HCT-116 cells were treated with 12.5 and 25 µM of the Cu complexes, stained for ɣH2AX and observed under the fluorescence microscope. Images were taken using 100x magnification.
| Subject area | |
| More specific subject area | |
| Type of data | |
| How data was acquired | |
| Data format | |
| Experimental factors | |
| Experimental features | |
| Data source location | |
| Data accessibility |